# Evaluate Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of BCD-261 After Single Subcutaneous Injection in Healthy Chinese Volunteers

> **NCT07535775** · PHASE1 · NOT_YET_RECRUITING · sponsor: **SPH-BIOCAD (HK) Limited** · enrollment: 48 (estimated)

## Conditions studied

- Healthy Adult Participants

## Interventions

- **DRUG:** BCD-261

## Key facts

- **NCT ID:** NCT07535775
- **Lead sponsor:** SPH-BIOCAD (HK) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-06
- **Primary completion:** 2026-10-10
- **Final completion:** 2027-03-20
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07535775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07535775, "Evaluate Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of BCD-261 After Single Subcutaneous Injection in Healthy Chinese Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07535775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*